Patents Represented by Attorney, Agent or Law Firm Robert P. Blackburn
-
Patent number: 6759417Abstract: Organic compounds having the structural formulas I, II, and III are provided where the variables have the values described herein and R1 and R2 in structure I join together to form a 5 to 7 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group in structures I and II. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: June 2, 2003Date of Patent: July 6, 2004Assignee: Chiron CorporationInventors: Paul A. Renhowe, Cynthia M. Shafer
-
Patent number: 6756383Abstract: Organi c compounds having the structural formulas I, II, and III are provided where the variables have the values described herein and R1 and R2 in structure I join together to form a 5 to 7 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group in structures I and II. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: August 30, 2001Date of Patent: June 29, 2004Assignee: Chiron CorporationInventors: Paul A. Renhowe, Timothy D. Machajewski, Cynthia M. Shafer, Mary Ellen Wernette Hammond, Sabina Pecchi
-
Patent number: 6756359Abstract: Antimicrobial macrolide compounds are provided having formulas II: as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.Type: GrantFiled: July 3, 2002Date of Patent: June 29, 2004Assignee: Chiron CorporationInventors: Daniel Chu, Matthew Burger, Xiaodong Lin, Georgia Law Carroll, Jacob Plattner, Alice Rico
-
Patent number: 6753015Abstract: Microparticles with adsorbed complexes of macromolecule and detergent, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(&agr;-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surfaces of the microparticles have adsorbed thereon a complex of biologically active macromolecules, such as nucleic acids, polypeptides, antigens, and adjuvants, and a detergent. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferably those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 30,000 Daltons to 70,000 Daltons. Preferred macromolecules are bacterial and viral antigens (such as HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens) as well as polynucleotides that encode for such antigens.Type: GrantFiled: September 28, 2001Date of Patent: June 22, 2004Assignee: Chiron CorporationInventors: Jia-Hwa Fang, Mammohan Singh, Derek O'Hagan, Maninder Hora
-
Patent number: 6743602Abstract: The present invention features human HX2004-6 polypeptide and nucleotide sequences encoding HX2004-6 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human HX2004-6 polypeptide. The present invention also relates to antibodies that bind specifically to a human HX2004-6 polypeptide. Further provided are diagnostic and screening methods using HX2004-6 polynucleotides and antibodies specific for HX2004-6 polypeptides.Type: GrantFiled: July 25, 2000Date of Patent: June 1, 2004Assignee: Chiron CorporationInventor: Giulia C. Kennedy
-
Patent number: 6740323Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.Type: GrantFiled: November 22, 2000Date of Patent: May 25, 2004Assignee: Chiron CorporationInventors: Mark Selby, Edward Glazer, Michael Houghton
-
Patent number: 6737233Abstract: A 24 kd percent capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purication of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.Type: GrantFiled: February 17, 1998Date of Patent: May 18, 2004Assignee: Chiron S.r.l.Inventor: Sergio Abrignani
-
Patent number: 6730297Abstract: Gene delivery vectors, for example, recombinant FIV vectors, and methods of using such vectors are provided for use in treating or preventing retinal diseases of the eye and diseases of the brain associated with lysosomal storage disorders.Type: GrantFiled: May 26, 2000Date of Patent: May 4, 2004Assignees: Chiron Corporation, University of Iowa Research FoundationInventors: Beverly Davidson, Douglas J. Jolly, Sybille L. Sauter, Colleen S. Stein, Thomas W. Dubensky, Jr., Jason A. Heth
-
Patent number: 6727273Abstract: Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.Type: GrantFiled: September 18, 2001Date of Patent: April 27, 2004Assignee: Chiron CorporationInventors: Verena D. Huebner, Xiaodong Lin, Ian James, Liya Chen, Manoj Desai, Beata Krywult, Rajinder Singh, Liang Wang
-
Patent number: 6716624Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: July 31, 2002Date of Patent: April 6, 2004Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 6716626Abstract: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.Type: GrantFiled: November 16, 2000Date of Patent: April 6, 2004Assignees: Chiron Corporation, Kyoto UniversityInventors: Nobuyuki Itoh, Michael Kavanaugh
-
Patent number: 6713072Abstract: Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating, a microorganism transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.Type: GrantFiled: June 17, 1994Date of Patent: March 30, 2004Assignee: Chiron S.r.l.Inventors: Mariagrazia Pizza, Antonella Bartoloni, Rino Rappuoli
-
Patent number: 6709660Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: GrantFiled: April 30, 1999Date of Patent: March 23, 2004Assignee: Chrion S.r.l.Inventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Patent number: 6706496Abstract: Compositions and methods for expression of heterologous mammalian proteins and their secretion in the biologically active mature form using a yeast host cell as the expression system are provided. Compositions of the invention are nucleotide sequences encoding a signal peptide sequence for a yeast secreted protein, an optional leader peptide sequence for a yeast secreted protein, a native propeptide leader sequence for a mature protein of interest, and a sequence for the mature protein of interest, all operably linked to a yeast promoter. Each of these elements is associated with a processing site recognized in vivo by a yeast proteolytic enzyme. Any or all of these processing sites may be a preferred processing site that has been modified or synthetically derived for more efficient cleavage in vivo. The compositions are useful in methods for expression of heterologous mammalian proteins and their secretion in the biologically active mature form.Type: GrantFiled: August 2, 2001Date of Patent: March 16, 2004Assignee: Chiron CorporationInventor: Patricia Tekamp-Olson
-
Patent number: 6703221Abstract: The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.Type: GrantFiled: August 17, 2000Date of Patent: March 9, 2004Assignee: Chiron CorporationInventors: Vivien Chan, Michael Rohan, Lewis T. Williams
-
Patent number: 6699844Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.Type: GrantFiled: December 3, 2002Date of Patent: March 2, 2004Assignee: Chiron CorporationInventors: Richard E. Jones, Ning Y. Yu
-
Patent number: 6692907Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.Type: GrantFiled: May 9, 1995Date of Patent: February 17, 2004Assignee: Chiron CorporationInventors: Amy J. Weiner, Michael Houghton
-
Patent number: 6689879Abstract: Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified in the region of amino acids 420-436 so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.Type: GrantFiled: December 30, 1999Date of Patent: February 10, 2004Assignee: Chiron CorporationInventors: Susan Barnett, Karin Hartog, Eric Martin
-
Patent number: 6677301Abstract: The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues. C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF163 N-terminus. The present invention also relates to a DNA molecule encoding KGFdes1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGFdes1-23 by culturing the transformed host. The present invention further relates to a conjugate of KGFdes1-23 and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidermis.Type: GrantFiled: May 16, 2000Date of Patent: January 13, 2004Assignee: Chiron CorporationInventors: Denis J. Gospodarowicz, Frank R. Masiarz
-
Patent number: 6676938Abstract: The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B Streptococcus (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.Type: GrantFiled: May 17, 2001Date of Patent: January 13, 2004Assignee: Chiron S.r.L.Inventors: Giuseppe Teti, Luciano Polonelli